Imugene

Imugene Limited (ASX:IMU) is an Australian clinical-stage immuno-oncology company focused on developing a range of novel immunotherapies designed to activate the immune system of cancer patients to treat and eradicate tumors.

Overview:

Imugene's core technology revolves around B-cell activating immunotherapies aimed at generating a broad T-cell response against cancer. The company's pipeline includes several oncolytic viruses and vaccine technologies, including:

• HER-Vaxx: A B-cell activating peptide-based cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor.
• PD1-Vaxx: A B-cell activating cancer immunotherapy designed to treat tumors that express PD-L1. It aims to produce an antibody response that blocks the PD-1/PD-L1 interaction, releasing the immune system to attack cancer cells.
• CF33 (Vaxinia): An oncolytic virus designed to selectively infect and destroy cancer cells, as well as stimulate the immune system to attack remaining cancer cells.
• CHECKvacc: An oncolytic virus combined with a checkpoint inhibitor.

Research and Development:

Imugene conducts preclinical and clinical research to evaluate the safety and efficacy of its immunotherapies. Its clinical trials are often conducted in collaboration with leading cancer centers around the world.

Business Strategy:

Imugene's business strategy involves developing its immunotherapy pipeline through clinical trials, seeking strategic partnerships, and potentially out-licensing or commercializing its products. The company is publicly listed on the Australian Securities Exchange (ASX).

Scientific Basis:

The scientific rationale behind Imugene's immunotherapies lies in harnessing the power of the patient's own immune system to fight cancer. By activating B-cells, the company aims to generate antibodies and a broader T-cell response that can target and eliminate tumor cells. Oncolytic viruses are designed to directly kill cancer cells and also stimulate an immune response against the tumor.